3 'Under the Radar' Stocks To Watch Amid Coronavirus

These healthcare firms may be poised for gains

Feb 13, 2020

SMITH BRAIN TRUST  Worldwide fear about the coronavirus is likely to result in the outperformance of health stocks in the near future, Maryland Smith’s David Kass said this week, speaking to a reporter from InvestorPlace. His comments came as global health officials reported a slowdown in the number of new cases of the virus. The outbreak had reportedly infected more than 45,000 people worldwide and killed more than 1,100.

“Since many analysts have recommended investments in biotech stocks that are trying to develop a vaccine for this virus, those particular stocks have already had large stock moves to the upside,” said Kass, clinical professor of finance at the University of Maryland’s Robert H. Smith School of Business. “Instead of those highly visible potential beneficiaries of the spreading of this disease, I suggest looking elsewhere within the healthcare sector.”

In particular, he said, he would look to buy stocks that are currently “under the radar” for this possible epidemic, ones that stand to benefit from the increase in healthcare spending that’s likely to come in the years ahead, as a result of the outbreak.

Here are Kass’ recommendations:

(1) DaVita (NYSE:DVA) provides dialysis services for patients with chronic kidney failure through outpatient facilities and hospitals in the U.S. It also offers ancillary services, including lab/pharmacy services and physician network management. Recently its earnings have been growing rapidly and it has issued a very bright outlook. Twenty-three percent of its shares are owned by Berkshire Hathaway.

(2) CVS Health (NYSE:CVS) is the largest pharmacy health care provider in the U.S. and recently acquired Aetna. As the nation's foremost integrated health-care services provider, its revenues and profits are projected to grow at a rapid rate in the years ahead.

(3) Johnson & Johnson (NYSE:JNJ) is a worldwide leader in the pharmaceutical, medical devices and consumer healthcare products industries. It is likely to continue experiencing rapid growth in revenues and earnings in the foreseeable future.




About the Expert(s)

David Kass

Dr. David Kass has published articles in corporate finance, industrial organization, and health economics. He currently teaches Advanced Financial Management and Business Finance, and is the Faculty Champion for the Sophomore Finance Fellows. Prior to joining the faculty of the Smith School in 2004, he held senior positions with the Federal Government (Federal Trade Commission, General Accounting Office, Department of Defense, and the Bureau of Economic Analysis). Dr. Kass has recently appeared on Bloomberg TV, CNBC, PBS Nightly Business Report, Maryland Public Television, Business News Network TV (Canada), FOX TV, Bloomberg Radio, Wharton Business Radio, KCBS Radio, American Public Media's Marketplace Radio, and WYPR Radio (Baltimore), and has been quoted on numerous occasions by The Wall Street Journal, Bloomberg News, The New York Times and The Washington Post, where he has primarily discussed Warren Buffett, Berkshire Hathaway, the economy, and the stock market. 

More In


Is It Time To Refinance Your House?

With mortgage rates recently falling to a three-year low, maybe you’ve been wondering whether it might be time to refinance. Our expert has the math to help you decide.

Feb 13, 2020
Why Declining Population Growth Is Reason To Worry

The U.S. population had expanded a mere 0.5% last year, the least in a century, weighed by a steadily falling birth rate and a sharp decline in immigration. Here's what that means for the economy – and what policymakers can do about it.

Jan 30, 2020
What GE CEO Culp Is Getting Right

Analysts may disagree on General Electric stock prospects, but there’s one thing they do seem to agree on: the effectiveness of CEO Larry Culp.

Jan 24, 2020